101. N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression.
- Author
-
Du NN, Peng ZG, Bi CW, Tang S, Li YH, Li JR, Zhu YP, Zhang JP, Wang YX, Jiang JD, and Song DQ
- Subjects
- Alkaloids adverse effects, Alkaloids pharmacokinetics, Animals, Antiviral Agents adverse effects, Antiviral Agents chemistry, Antiviral Agents pharmacokinetics, Antiviral Agents pharmacology, Cell Line, Humans, Male, Mice, Mice, Inbred ICR, Quinolizines adverse effects, Quinolizines pharmacokinetics, Safety, Structure-Activity Relationship, Matrines, Alkaloids chemistry, Alkaloids pharmacology, Down-Regulation drug effects, HSC70 Heat-Shock Proteins metabolism, Hepacivirus drug effects, Hepacivirus physiology, Quinolizines chemistry, Quinolizines pharmacology, Virus Replication drug effects
- Abstract
Heat-stress cognate 70 (Hsc70) is a host factor that helps hepatitis C virus (HCV) to complete its life cycle in infected hepatocytes. Using Hsc70 as a target for HCV inhibition, a series of novel N-substituted benzyl matrinic/sophoridinic acid derivatives was synthesized and evaluated for their anti-HCV activity in vitro. Among these analogues, compound 7c possessing N-p-methylbenzyl afforded an appealing ability to inhibit HCV replication with SI value over 53. Furthermore, it showed a good oral pharmacokinetic profile with area-under-curve (AUC) of 13.4 µM·h, and a considerably good safety in oral administration in mice (LD50>1000 mg/kg). As 7c suppresses HCV replication via an action mode distinctly different from that of the marketed anti-HCV drugs, it has been selected as a new mechanism anti-HCV candidate for further investigation, with an advantage of no or decreased chance to induce drug-resistant mutations.
- Published
- 2013
- Full Text
- View/download PDF